Entry Nº 75Programme

Advertising & Design Awards

Novartis takes Cannes Lions Pharma Grand Prix with prostate campaign

Novartis has won the Pharma Grand Prix at the Cannes Lions International Festival of Creativity for its 'Relax Your Tight End' prostate cancer awareness campaign, taking the top pharma creative prize.

Novartis’ ‘Relax Your Tight End’ prostate cancer campaign wins Cannes Lions Pharma Grand Prix - Fierce Pharma
PhotoNovartis’ ‘Relax Your Tight End’ prostate cancer campaign wins Cannes Lions Pharma Grand Prix - Fierce Pharma — geralt / pixabay

Judges’ notes

  1. Novartis won the Pharma Grand Prix at the Cannes Lions International Festival of Creativity
  2. The campaign is titled 'Relax Your Tight End' and addresses prostate cancer awareness
  3. Only one Pharma Grand Prix is awarded per festival, the top prize in the Lions Health pharma track
  4. The campaign uses football vocabulary — the 'tight end' position — as a public-health wordplay device
  5. The win positions the campaign as a benchmark for the Clio Health, MM+M, Effie Health, and D&AD juries

Novartis has won the Pharma Grand Prix at the Cannes Lions International Festival of Creativity for its prostate cancer awareness campaign "Relax Your Tight End."

The Swiss pharmaceutical company took the top prize in the festival's pharma category, the highest honor in healthcare creative work.

What does a Pharma Grand Prix entail?

A Pharma Grand Prix goes to a single entry the pharma jury selects as the year's creative benchmark in healthcare marketing. The award sits above Gold Lion in the pharma track, with only one Grand Prix handed out per festival.

The pharma jury operates separately from the broader Lions Health jury. Lions Health shortlists entries from the global pool of healthcare submissions, then the pharma jury selects Gold, Silver, and Bronze Lions, plus the single Grand Prix.

How does "Relax Your Tight End" operate?

The campaign title borrows the football term "tight end" and reframes it as a colloquial prompt for prostate health. The wordplay turns sports vocabulary into a public-health nudge.

That wordplay is the work's central creative device. Prostate cancer remains one of the most common cancers in men globally, and screening rates in many markets continue to fall short of public-health targets. Pharma juries have favored campaigns that crack through stigma with cultural fluency, and "Relax Your Tight End" follows that template.

What does the win signal for the awards race?

Grand Prix winners at Cannes Lions typically anchor a campaign's run through the rest of the awards season. "Relax Your Tight End" is now positioned as a benchmark for the Clio Health, MM+M, Effie Health, and D&AD juries.

The win also marks continued jury appetite for consumer-style work in pharma. Recent Grand Prix recipients have leaned on humor, sports, and pop-culture cues rather than clinical or scientific framing.

Who created the campaign?

The headline-level coverage from Fierce Pharma did not identify the agency. Cannes Lions publishes full agency credits with each Grand Prix trophy on its archive, typically including the lead creative, production, and media partners.

What does a Pharma Grand Prix change in the race?

A Pharma Grand Prix concentrates industry attention on a single campaign for the rest of the cycle. Holding companies reference Grand Prix wins in new-business pitches, and brands cite them in annual brand-equity reports.

Novartis now has a centerpiece case study for its oncology and men's-health portfolios. Both categories have drawn increased direct-to-consumer investment from major pharmaceutical companies in recent years.

What's next on the pharma-marketing calendar?

Pharma-marketing awards still ahead include the MM+M Awards, Clio Health, the Effie Health Awards, and D&AD. Cannes Lions Grand Prix winners historically perform strongly across these programs.

via Google News: Cannes Lions advertising awards (Source)

Filed under

  • cannes-lions
  • pharma-grand-prix
  • novartis
  • healthcare-marketing
  • relax-your-tight-end
Share this article:

More from Daniel Okafor

Daniel Okafor

Show full bio

Senior reporter covering companies, deals and strategy in awards industry at Awards Review.

93 articles